July 18 (Reuters) - Cogentix Medical Inc ::Cogentix Medical signs agreement to launch endo-urology product line in U.S.; launch to further increase urology products growth rate during 2018.Says ‍continue to have $27 million in cash and investments for additional business development opportunities​.Cogentix Medical - transaction is expected to further increase co's strong urology product revenue growth rate, which was about 11 percent during q2 2017.Says ‍expect to complete at least one more transaction in near term​.
Full Article

Cogentix Medical Inc : Robert C. Kill , chairman of board and CEO, will resign as a director and officer of Cogentix . Darin Hammers , current chief operating officer, will be named as interim CEO . Cogentix and its board of directors have agreed to support proposals set forth in definitive proxy statement filed by Lewis C. Pell . Directors Kevin Roche and Ken Paulus will also depart Cogentix pursuant to settlement agreement .Cogentix Medical announces settlement agreement in connection with proxy contest and related litigation and leadership changes; annual meeting to be held may 24, 2016 at 12:00 p.m. Central daylight time.
Full Article

Reuters, the news and media division of Thomson Reuters, is the world’s largest international multimedia news provider reaching more than one billion people every day. Reuters provides trusted business, financial, national, and international news to professionals via Thomson Reuters desktops, the world's media organizations, and directly to consumers at Reuters.com and via Reuters TV. Learn more about Thomson Reuters products: